EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Updates and advances in pyruvate kinase deficiency

Neeti Luke, Kirsty Hillier, Hanny Al-Samkari, Rachael F Grace

Trends in Molecular Medicine · 2023

DOI: 10.1016/j.molmed.2023.02.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Molecular Medicine, 2023. Verfasst von Neeti Luke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Hematology-Oncology, Hassenfeld Children's Hospital at NYU Langone Health, NYU Grossman School of Med…. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Congenital Nonspherocytic, Pyruvate Metabolism, Inborn Errors. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Novartis, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the PKLR gene lead to pyruvate kinase (PK) deficiency, causing chronic hemolytic anemia secondary to reduced red cell energy, which is crucial for maintenance of the red cell membrane and function. Heterogeneous clinical manifestations can result in significant morbidity and reduced health-related quality of life. Treatment options have historically been limited to supportive care, including red cell transfusions and splenectomy. Current disease-modifying treatment considerations include an oral allosteric PK activator, mitapivat, which was recently approved for adults with PK deficiency, and gene therapy, which is currently undergoing clinical trials. Studies evaluating the role of PK activators in other congenital hemolytic anemias are ongoing. The long-term effect of treatment with disease-modifying therapy in PK deficiency will require continued evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolytic, Congenital NonspherocyticPyruvate Metabolism, Inborn ErrorsAdultQuality of LifeHumansPyruvate Kinase

Stichwörter der Autor:innen

congenital hemolytic anemiagene therapymitapivatpyruvate kinase deficiencytransfusions

Substanzen

Pyruvate Kinase

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Hematology-Oncology, Hassenfeld Children's Hospital at NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA. Electronic address: Rachael.Grace@childrens.harvard.edu.

Förderung

  • NHLBI NIH HHS
  • Novartis
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • American Society of Hematology

Zitieren

APA

Luke, N., Hillier, K., Al-Samkari, H., & Grace, R. F. (2023). Updates and advances in pyruvate kinase deficiency. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2023.02.005

Vancouver

Luke N, Hillier K, Al-Samkari H, Grace RF. Updates and advances in pyruvate kinase deficiency. Trends in Molecular Medicine. 2023. doi:10.1016/j.molmed.2023.02.005

BibTeX
@article{Luke2023,
  author = {Luke, Neeti and Hillier, Kirsty and Al-Samkari, Hanny and Grace, Rachael F},
  title = {Updates and advances in pyruvate kinase deficiency},
  journal = {Trends in Molecular Medicine},
  year = {2023},
  doi = {10.1016/j.molmed.2023.02.005}
}
Kostenlos starten →